Eli Lilly said on Monday ​it would buy ​privately ​held blood cancer treatment developer Ajax Therapeutics for up to $2.3 ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

With the ink barely dry on an agreement to buy Kelonia, Eli Lilly has signed a deal to take ownership of Ajax Therapeutics ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

Eli Lilly (NYSE:LLY) agreed to acquire Ajax Therapeutics for up to $2.3b, adding a Type II JAK2 inhibitor program for ...

Lilly will pay up to $2.3B for Ajax and its AJ1‑11095 myelofibrosis drug; proof‑of‑concept data expected in 2026.

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...

Indianapolis-based drug giant Eli Lilly and Co. on Monday announced an agreement to acquire cancer-drug developer Ajax ...

Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used ...

Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters ...

Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, securing rights to its experimental myelofibrosis treatment AJ1-11095. The once-daily oral JAK2 inhibitor is in early-stage trials for ...